NEW YORK – Clinical state immunotherapy company UbiVac said on Tuesday that it is collaborating with Bristol Myers Squibb on a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a cancer vaccine with a T cell agonist and a PD-1 checkpoint inhibitor.
The Phase IB trial will test whether UbiVac's investigational cancer vaccine DPV-001 combined with BMS' T cell agonist BMS-986178 and nivolumab (Opdivo) can stimulate anti-cancer immunity in advanced triple-negative breast cancer patients.